Palmitoyl tripeptide-1 is a cosmetic ingredient made by attaching palmitic acid to GHK, the glycine-histidine-lysine tripeptide. It is one of the two peptides in the trade-name blend Matrixyl 3000. This guide covers its structure, naming, research and safety review. Sources were checked on November 17, 2026.
Quick answer: Palmitoyl tripeptide-1 is Pal-Gly-His-Lys, a fatty-acid-linked form of the GHK peptide. CosIng lists it as a skin conditioning ingredient. It was once sold under the vague name palmitoyl oligopeptide. Evidence is mostly laboratory work plus small supplier studies.
Vitrapep does not sell palmitoyl tripeptide-1; this page is a reference summary of published research and regulatory information.
What is palmitoyl tripeptide-1?
Palmitoyl tripeptide-1 is a lipopeptide, a peptide joined to a fatty acid. CIR describes it as three amino acids, glycine, histidine and lysine, “connected via an amide bond at its N-terminus to palmitic acid” (CIR, 2014). PubChem lists the formula C30H54N6O5 and a molecular weight of 578.8 g/mol (PubChem CID 10231864). Our peptide primer explains the basics.
CIR calls the GHK sequence “a liver growth factor peptide and a fragment of type I collagen.” Tripeptide-1 is the INCI name for GHK itself, and copper tripeptide-1 is its copper complex. Our GHK-Cu guide covers that copper form.
The name changed over time. CIR explains that the vague name “palmitoyl oligopeptide” was retired because it covered two ingredients. Those are now palmitoyl tripeptide-1 (GHK) and palmitoyl hexapeptide-12 (VGVAPG). PubChem still lists “palmitoyl oligopeptide” and Biopeptide CL as synonyms. CIR describes Biopeptide CL and Maxi-Lip as trade-name materials containing Pal-GHK. Croda lists palmitoyl tripeptide-1 in the INCI listing for Matrixyl 3000 (Croda, 2026).
Palmitoyl tripeptide-1: key facts
| Fact | Detail |
|---|---|
| INCI name | Palmitoyl Tripeptide-1 (formerly part of “palmitoyl oligopeptide”) |
| Structure type | Lipopeptide: palmitoyl group on the tripeptide GHK |
| Sequence | Pal-Gly-His-Lys (Pal-GHK) |
| Molecular formula | C30H54N6O5 |
| Molecular weight | 578.8 g/mol |
| Main cosmetic function (CosIng) | Skin conditioning |
| Trade name(s) | Biopeptide CL, Maxi-Lip; one of two peptides in Matrixyl 3000 |
How does palmitoyl tripeptide-1 work?
The idea is to deliver a collagen-derived signal into skin. In 2000, Lintner, of Sederma, and Peschard noted that short peptides are highly soluble and fragile, which limits cosmetic use. They reported that adding long fatty acid chains improves skin penetration and specific activity (Lintner and Peschard, 2000). Palmitoyl tripeptide-1 is one example of that approach.
CIR summarized data from Lintner and Peschard showing a strong signal of collagen synthesis when human fibroblasts were exposed to Pal-GHK. A gene panel of 450 genes pointed toward keratinocyte anchoring and differentiation genes. CIR noted that additional details were not provided (CIR, 2014). A 2020 review groups Pal-GHK with “signal peptides” that modulate skin protein turnover (Errante et al., 2020).
What is palmitoyl tripeptide-1 used for?
CosIng lists one function: skin conditioning. Its record describes the ingredient as “the reaction product of palmitic acid and Tripeptide-1” (CosIng, 2026). FDA registration data cited by CIR in 2014 showed just 1 use under the name palmitoyl tripeptide-1. Another 519 uses were listed under the retired name palmitoyl oligopeptide, whose sequence was not stated.
Under US law, intended use decides whether a product is a cosmetic or a drug. Claims to affect the structure or function of the body can make a product a drug (FDA, 2024).
What does the research show?
The human data are small and come mainly from Sederma scientists. We found no large, independent, placebo-controlled trial of palmitoyl tripeptide-1 alone.
Eye-area study. CIR summarized a blind, vehicle-controlled test in 15 women aged 44 to 59. After 28 days, skin replicas showed a 39% decrease in wrinkle length, 23% in wrinkle depth and 17% in roughness. The placebo cream had no significant effect (CIR, 2014). CIR’s source was a 2000 trade-journal article by a Sederma author.
Skin thickness study. In 23 healthy women, ultrasound showed a small but significant increase in skin thickness, about 4% versus vehicle, after 4 weeks. CIR attributes this study to Lintner and Peschard (2000).
Penetration study. In 2026, a Nottingham team tested a serum containing Matrixyl 3000 on three female volunteers. OrbiSIMS detected Pal-GHK in every stratum corneum layer, with signal falling with depth. The data suggested the peptide sat on the outer surfaces of skin cells (Trzaska et al., 2026). Two authors worked for a cosmetics company.
What safety data exist?
The CIR Expert Panel reviewed palmitoyl tripeptide-1 with tripeptide-1, copper tripeptide-1, hexapeptide-12, palmitoyl tetrapeptide-7 and related ingredients. Its final report of June 30, 2014, found them “safe in the present practices of use and concentration in cosmetics” (CIR, 2014). The report was later published in a journal (Johnson et al., 2018). Data on Pal-GHK materials include:
- Maxi-Lip: no irritation in a single patch test on 10 volunteers.
- Maxi-Lip: a repeated insult patch test on 52 subjects found barely perceptible to moderate transient reactions, judged clinically insignificant.
- Biopeptide CL: slightly irritating to rabbit eyes, not irritating to rabbit skin, and not sensitizing in guinea pigs.
- Maxi-Lip was classed as an irritant in an egg-membrane eye irritation test.
- Both materials were negative in Ames bacterial mutation tests.
CIR also noted a laboratory finding for GHK itself. It stimulated growth of HeLa and KB tumor cells, but not normal WI-38 cells. No published carcinogenicity or reproductive toxicity data were found. CosIng lists no EU restrictions and no SCCS opinion for palmitoyl tripeptide-1.
What is palmitoyl tripeptide-1’s regulatory status, and how is it used in research?
In the United States, cosmetic products and ingredients, other than color additives, need no FDA approval before sale (FDA, 2025). Palmitoyl tripeptide-1 is a cosmetic ingredient, not an FDA-approved drug.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) became law on December 29, 2022. It added facility registration, product listing, serious adverse event reporting, safety substantiation records and mandatory recalls (FDA Voices, 2026). In the EU, CosIng lists it under CAS 147732-56-7 with an active status.
In analytical research, Pal-GHK has served as an internal standard. A 2009 LC-MS/MS method used it to measure palmitoyl pentapeptide-4 in finished creams (Chirita et al., 2009). Our LC-MS identity guide explains the technique.
Frequently asked questions about palmitoyl tripeptide-1
Is palmitoyl tripeptide-1 the same as GHK-Cu?
No. Both use the GHK sequence, but palmitoyl tripeptide-1 carries a palmitoyl fatty acid group, while GHK-Cu is GHK bound to copper.
Is it the same as palmitoyl oligopeptide?
Partly. CIR says the retired name palmitoyl oligopeptide covered two ingredients: palmitoyl tripeptide-1 and palmitoyl hexapeptide-12.
Is palmitoyl tripeptide-1 the same as Matrixyl 3000?
No. Matrixyl 3000 is a blend whose INCI listing includes palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
Is palmitoyl tripeptide-1 approved by the FDA?
No. FDA does not approve cosmetic ingredients, other than color additives, before they go on the market.
How does it relate to Matrixyl?
Original Matrixyl is palmitoyl pentapeptide-4, a different peptide. See our Matrixyl guide.
What to know now
- Structure: palmitic acid on GHK; C30H54N6O5; 578.8 g/mol.
- Name: once part of “palmitoyl oligopeptide”; trade names Biopeptide CL and Maxi-Lip.
- Blend: one of two peptides in Matrixyl 3000.
- Evidence: fibroblast data and two small supplier studies in 15 and 23 women.
- Safety: CIR found it safe as used in 2014; patch tests showed only minor reactions.
- Status: a cosmetic ingredient, not an FDA-approved drug.
What we’re watching
FDA rules under MoCRA. The MoCRA page, updated October 29, 2026, lists good manufacturing practice and fragrance allergen labeling rules that the law requires (FDA, 2026). Related guides: palmitoyl tripeptide-38 and peptides in skincare.